Charles River Laboratories International, Inc. $CRL Stock Position Decreased by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lowered its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 40.1% during the second quarter, HoldingsChannel.com reports. The fund owned 5,265 shares of the medical research company’s stock after selling 3,530 shares during the period. Los Angeles Capital Management LLC’s holdings in Charles River Laboratories International were worth $799,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in the stock. Fox Run Management L.L.C. bought a new stake in shares of Charles River Laboratories International in the 2nd quarter worth approximately $400,000. Cornerstone Investment Partners LLC grew its stake in Charles River Laboratories International by 6.3% during the 2nd quarter. Cornerstone Investment Partners LLC now owns 2,055 shares of the medical research company’s stock worth $312,000 after buying an additional 121 shares during the last quarter. Pekin Hardy Strauss Inc. increased its position in Charles River Laboratories International by 64.1% in the second quarter. Pekin Hardy Strauss Inc. now owns 38,391 shares of the medical research company’s stock worth $5,825,000 after buying an additional 14,996 shares during the period. Huntington National Bank lifted its stake in Charles River Laboratories International by 126.8% in the second quarter. Huntington National Bank now owns 676 shares of the medical research company’s stock valued at $103,000 after buying an additional 378 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Charles River Laboratories International by 11.8% during the second quarter. Bank of New York Mellon Corp now owns 386,049 shares of the medical research company’s stock valued at $58,575,000 after acquiring an additional 40,720 shares during the period. 98.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CRL. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, October 8th. TD Cowen dropped their price target on shares of Charles River Laboratories International from $205.00 to $197.00 and set a “buy” rating on the stock in a research note on Monday. Baird R W raised Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. Mizuho increased their price objective on Charles River Laboratories International from $155.00 to $174.00 and gave the stock a “neutral” rating in a report on Friday, October 17th. Finally, Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $188.29.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the completion of the sale, the executive vice president owned 24,116 shares in the company, valued at $3,800,681.60. This represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Down 1.5%

Charles River Laboratories International stock opened at $168.97 on Friday. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $208.10. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The stock has a market capitalization of $8.32 billion, a PE ratio of -127.05, a price-to-earnings-growth ratio of 4.83 and a beta of 1.53. The firm has a 50 day simple moving average of $168.69 and a 200-day simple moving average of $156.66.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, topping the consensus estimate of $2.32 by $0.11. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The firm’s quarterly revenue was down .5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.59 earnings per share. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).